TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates
NCT01319435 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2015-10-12
Summary
Phase I, open-label study to evaluate the pharmacokinetics, tolerability and short-term safety of ciprofloxacin in neonates with suspected (or proven) Gram Negative infection. Objectives: To evaluate the multiple-dose pharmacokinetics of ciprofloxacin in neonates and young infants (24 - 52 weeks postmenstrual age) with suspected or proven Gram Negative infection.
To evaluate the tolerability and describe short-term safety of ciprofloxacin in neonates and young infants with suspected (or proven) Gram Negative infection.
To describe the clinical outcomes of neonates treated with ciprofloxacin
Conditions
- Pharmacokinetics of Ciprofloxacin in Neonates
Interventions
- PROCEDURE
-
Collection of biological samples
Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7). Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces
Sponsors & Collaborators
-
University of Liverpool
collaborator OTHER -
Liverpool Women's NHS Foundation Trust
lead OTHER
Principal Investigators
-
Mark A Turner, MD · University of Liverpool/Liverpool Women's Hospital
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 24 Weeks
- Max Age
- 52 Weeks
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-31
- Primary Completion
- 2012-11-30
- Completion
- 2013-11-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Oral Amoxicillin and Cephalexin PK/PD in Neonates
NCT04916951 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections
NCT00621192 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)
NCT01728363 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
NCT01026636 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
NCT01019395 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants
NCT00942149 ·Status: COMPLETED ·Phase: PHASE1
-
Validation of Biomarkers Performance to Reduce Antibiotics overUse in newBorns With Suspected Clinical Signs of InfectionS
NCT06058819 ·Status: RECRUITING
-
Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants
NCT01229046 ·Status: WITHDRAWN ·Phase: PHASE1
-
NICU Antibiotics and Outcomes Trial
NCT03997266 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
NCT04126031 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
NCT01026740 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes
NCT02600559 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy And Safety Of Short Course Antibiotic Therapy In Preterm Neonates With Early Onset Sepsis
NCT06197269 ·Status: COMPLETED ·Phase: NA
-
Pharmacodynamic Parameters of Two Different Doses of Cefepime
NCT00177736 ·Status: COMPLETED
-
Antibiotic Therapy for Early Onset Neonatal Sepsis
NCT03932123 ·Status: RECRUITING
-
Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation
NCT06974994 ·Status: RECRUITING ·Phase: NA
-
Antibiotic Safety (SCAMP)
NCT01994993 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
NCT00555061 ·Status: COMPLETED ·Phase: PHASE4
-
Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment
NCT00487019 ·Status: COMPLETED
-
Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
NCT01670435 ·Status: COMPLETED
-
Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia
NCT00771719 ·Status: TERMINATED ·Phase: PHASE1
-
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
NCT06426836 ·Status: RECRUITING ·Phase: NA
-
Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis
NCT03453177 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
NCT01744730 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants
NCT00189384 ·Status: UNKNOWN ·Phase: PHASE3